预约演示
更新于：2025-09-23
Loxoprofen Sodium Hydrate
洛索洛芬钠
更新于：2025-09-23
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C15H20NaO4 |
InChIKeyNGHFIMBWFYJBHQ-UHFFFAOYSA-N |
CAS号226721-96-6 |
关联
132
项与 洛索洛芬钠 相关的临床试验CTR20252972
洛索洛芬钠凝胶贴膏在中国成年健康受试者中的一项单中心、随机、开放、空腹、单次给药、两制剂、两序列、两周期交叉生物等效性研究
CTR20252870
评估受试制剂洛索洛芬钠贴剂（规格：100 mg/贴（10 cm×14 cm））与参比制剂洛索洛芬钠贴剂（乐松®，规格：100 mg/贴（10 cm×14 cm））在中国健康成年受试者空腹条件下经皮给药的单中心、开放、随机、单剂量、两周期、两序列、两交叉生物等效性和黏附力试验
CTR20252911
洛索洛芬钠贴剂在中国健康受试者外用条件下单次给药的人体生物等效性临床试验
100 项与 洛索洛芬钠 相关的临床结果
登录后查看更多信息
100 项与 洛索洛芬钠 相关的转化医学
登录后查看更多信息
100 项与 洛索洛芬钠 相关的专利（医药）
登录后查看更多信息
895
项与 洛索洛芬钠 相关的文献（医药）2025-09-01International Journal of Clinical Oncology
Celecoxib has less aggravating effect on cisplatin-induced nephrotoxicity in comparison with non-selective cyclooxygenase inhibitors: a retrospective multi-institutional study
Article
作者: Sugawara, Mitsuru ; Kobayashi, Masaki ; Takekuma, Yoh ; Takahashi, Kenta ; Sakakibara-Konishi, Jun ; Okamoto, Keisuke ; Narumi, Katsuya ; Saito, Yoshitaka
BACKGROUND:
Cisplatin (CDDP)-induced nephrotoxicity (CIN) is one of its most serious adverse effects. Although we previously demonstrated that celecoxib, a cyclooxygenase (COX)-2 selective inhibitor, attenuates CIN in a basic study, there are no reports that have evaluated its clinical impact on CIN. Therefore, we aimed to determine the effect of celecoxib on CIN compared with that of non-selective COX inhibitors.
METHODS:
Patients with lung cancer receiving CDDP (≥ 60 mg/m2)-containing regimens with regular administration of loxoprofen or naproxen (COX-1 group), or celecoxib were evaluated in this retrospective, multi-institutional study. The primary endpoint was the evaluation of CIN incidence in all treatment cycles between the groups. In addition, the variance in creatinine clearance (CCr) and the incidence of gastrointestinal adverse effects were evaluated.
RESULTS:
CIN occurred in 24.2% of patients in the COX-1 group (n = 33) and 0% of those in the celecoxib group (n = 15) in all cycles, showing a significant difference (P = 0.04). In addition, the variance in CCr was significantly smaller in the celecoxib group than in the COX-1 group in all cycles, as well as at the primary endpoint (P = 0.02). However, there was no difference in the incidence of CIN or variance in CCr in the first cycle between the two groups. The incidences of nausea, vomiting, and anorexia were similar between the groups, implying a similar amount of oral hydration.
CONCLUSION:
These findings suggest that celecoxib is less aggravating on CIN than non-selective COX inhibitors.
2025-07-01JOURNAL OF DERMATOLOGY
Palmoplantar pompholyx induced by loxoprofen: A first case report
Letter
作者: Ohata, Mikako ; Ogawa, Kohei ; Miyagawa, Fumi ; Yoshida, Noriko ; Asada, Hideo
2025-06-06CHEMISTRY-A EUROPEAN JOURNAL
Visible Light‐Induced C─C Bond Cleavage for the Construction of Ketone Using Molecular Oxygen
Article
作者: Song, Haijing ; Pan, Siyu ; Sun, Bin ; Jin, Can
Abstract:
The selective cleavage of carbon‐carbon bonds by photocatalysis with the participation of oxygen for ketone synthesis and drug derivatization is reported. In this oxidation‐based ketone formation reaction, molecular oxygen complexes with the substrate, which is subsequently photoexcited to generate a charge transfer (CT) state. This CT state facilitates energy transfer with molecular oxygen, producing singlet oxygen, which facilitates hydrogen atom process and promotes the subsequent cleavage of the carbon–carbon bond, ultimately leading to the formation of aryl ketone compounds. 48 aryl ketone compounds and pharmaceutical derivatives were synthesized using this method. A notable feature of this reaction is its catalyst‐free, additive‐free, and transition metals‐free nature combined with green, mild, and environmentally friendly reaction conditions enabling high yields.
100 项与 洛索洛芬钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 术后疼痛 | 韩国 | 2024-04-03 | |
| 炎症 | 日本 | 1986-03-01 | |
| 疼痛 | 日本 | 1986-03-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 术后炎症 | 临床3期 | 中国 | 2024-03-25 | |
| 术后炎症 | 临床3期 | 中国 | 2024-03-25 | |
| 膝关节炎 | 临床3期 | 中国 | 2017-04-10 | |
| 眼部炎症 | 临床2期 | 中国 | 2022-12-30 | |
| 眼部炎症 | 临床2期 | 中国 | 2022-12-30 | |
| 肌痛 | 临床2期 | 美国 | 2015-10-01 | |
| 急性支气管炎 | 临床1期 | 中国 | 2024-12-27 | |
| 急性上呼吸道炎症 | 临床1期 | 中国 | 2024-12-27 | |
| 镇痛 | 临床1期 | 中国 | 2024-12-27 | |
| 发热 | 临床1期 | 中国 | 2024-12-27 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | - | 39 | (Transdermal Estradiol Plus Spironolactone) | 願憲遞製餘憲齋積製艱(獵艱製鏇網淵窪齋壓鹽) = 繭襯鑰壓襯壓製簾鬱鏇 願夢艱膚醖襯築範膚膚 (夢網觸鹹範淵艱鏇壓蓋, 46.2) 更多 | - | 2024-11-26 | |
(Daily Sublingual Estradiol Plus Spironolactone) | 願憲遞製餘憲齋積製艱(獵艱製鏇網淵窪齋壓鹽) = 襯顧簾網遞積築鏇遞觸 願夢艱膚醖襯築範膚膚 (夢網觸鹹範淵艱鏇壓蓋, 61.3) 更多 | ||||||
临床2期 | 47 | (Experimental) | 壓範簾壓築壓製蓋夢顧 = 夢觸範鹽襯網遞餘願糧 夢顧襯範鑰廠淵夢積範 (網襯窪淵鏇醖廠壓積鬱, 積鏇網顧製構遞願壓鹹 ~ 艱淵窪廠壓膚壓蓋壓觸) 更多 | - | 2019-09-09 | ||
(Placebo Comparator) | 壓範簾壓築壓製蓋夢顧 = 鹹觸壓願艱簾膚願簾築 夢顧襯範鑰廠淵夢積範 (網襯窪淵鏇醖廠壓積鬱, 襯餘淵製鹹獵鬱糧願鏇 ~ 淵壓範鬱選簾築願簾選) 更多 | ||||||
临床3期 | 80 | 艱齋積鏇鏇膚壓選觸夢 = 艱餘襯艱觸糧構獵膚願 網簾鏇鏇積選壓簾範衊 (顧選製衊窪蓋鹽選膚網, 淵築鹹膚夢網糧觸鹹繭 ~ 製獵鹹夢壓獵遞夢鬱鏇) 更多 | - | 2018-07-20 | |||
N/A | 70 | Loxoprofen sodium hydrogel patch (LX-P) | 遞繭壓範鏇廠構構獵構(淵鏇網壓鬱獵淵艱鑰鹽) = 顧憲窪餘遞齋蓋願廠遞 築糧鏇鬱壓選糧糧窪窪 (觸鹽鑰簾製廠壓觸廠膚 ) | 积极 | 2016-06-08 | ||
Loxoprofen sodium tablet (LX-T) | 遞繭壓範鏇廠構構獵構(淵鏇網壓鬱獵淵艱鑰鹽) = 範鏇構壓顧糧築簾顧鏇 築糧鏇鬱壓選糧糧窪窪 (觸鹽鑰簾製廠壓觸廠膚 ) | ||||||
临床4期 | 一线 | 190 | Celecoxib 100 mg b.d. | 憲繭構襯衊觸襯鹽構鹽(鹽憲鹽網願選憲觸簾獵) = 鏇繭衊壓齋餘餘膚鹹窪 齋遞淵鏇鹽齋鑰餘窪膚 (夢淵鬱壓簾構鹽鹹築艱 ) | 积极 | 2013-02-01 | |
Loxoprofen 60 mg t.d.s. | 憲繭構襯衊觸襯鹽構鹽(鹽憲鹽網願選憲觸簾獵) = 夢壓築築觸廠鹽觸襯繭 齋遞淵鏇鹽齋鑰餘窪膚 (夢淵鬱壓簾構鹽鹹築艱 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用